We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · June 30, 2022

Driver Oncogene Variations and Outcomes in Patients With Locally Advanced NSCLC Treated With Chemoradiation and Consolidative Durvalumab

JAMA Network Open

 

Additional Info

JAMA Network Open
Association of Driver Oncogene Variations With Outcomes in Patients With Locally Advanced Non-Small Cell Lung Cancer Treated With Chemoradiation and Consolidative Durvalumab
JAMA Netw Open 2022 Jun 01;5(6)e2215589, Y Liu, Z Zhang, W Rinsurongkawong, CM Gay, X Le, MS Ning, J Lewis, V Rinsurongkawong, JJ Lee, J Roth, S Swisher, S Gandhi, PP Lee, DL Gibbons, AA Vaporciyan, JV Heymach, J Zhang, SH Lin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading